Impact of Obesity on Systemic Treatment Outcomes in Metastatic Urological Malignancies
A. Handke, M. Silberg, C. Orf, C. Loeffelholz, P. Bach, S. Berg, F. Roghmann, K. H. Tully · 2026
Read Impact of Obesity on Systemic Treatment Outcomes in Metastatic Urological Malignancies by A. Handke, M. Silberg, C. Orf, C. Loeffelholz, P. Bach, S. Berg, F. Roghmann, K. H. Tully (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13238925.txt.
Description
Handke and colleagues ask whether obesity helps or harms patients treated for advanced urological cancers. Extra weight is reshaping outcomes across oncology in surprising ways. Their study covers metastatic bladder, kidney, and prostate cancers, the three big cancers of the urinary and male reproductive systems, in patients given systemic drug therapy at one high-volume centre.
Looking back over cases treated from 2017 to 2025, the team compares survival between patients with and without obesity. Cancer doctors know this as the obesity paradox question: heavier patients sometimes live longer on modern drugs. A centre-level answer helps clinicians counsel patients honestly instead of assuming weight only ever works against them.
Catalog record
| CREATOR | A. Handke, M. Silberg, C. Orf, C. Loeffelholz, P. Bach, S. Berg, F. Roghmann, K. H. Tully |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |